A question the sources answer mostly by silence
Weight change around menopause is one of the most common reasons women look into GLP-1 medications, and the honest first thing to say is that the FDA-approved labels do not address it. This guide reports what can be reported: that the labels are silent on menopause, who was in the tirzepatide trial by sex and age, what the label does say about age and sex where it says anything, and what a 2026 review lists among the factors that affect response. It then sets out what to raise with a provider. It makes no claim about what tirzepatide does for menopausal weight change, because no source this site uses supports one.
This is general information and not medical advice. The label and trial describe Zepbound®, the branded product. Personalized Compounded tirzepatide, which Bodi Envi’s programs may include, is not FDA-approved, was not studied and is not equivalent to Zepbound®. Your licensed provider is the person to ask.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the labels say
Nothing. The word menopause does not appear anywhere in the Zepbound® prescribing information, and it does not appear in the Wegovy® label either. Neither label describes menopausal status as part of the indication, as a factor in dosing, as a warning or precaution, or as a subgroup in the clinical studies. The Zepbound® indication is for adults with obesity, or overweight and a weight-related condition, without reference to sex or life stage, in combination with a reduced calorie diet and increased physical activity.
That silence is worth reading correctly. It does not mean the medication works differently around menopause, and it does not mean it works the same. It means the manufacturer did not study menopause as a variable in the trials that supported approval, and the FDA-approved label therefore says nothing about it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Who was in the trial
SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022, is the Zepbound® label’s Study 1. According to the label’s description, it enrolled 2,539 adults with obesity or with overweight and a weight-related condition, excluding type 2 diabetes. At baseline the mean age was 45 years, with a range of 18 to 84, and 68 percent of participants were female. Mean body weight was 104.8 kg and mean body mass index was 38. The trial randomized participants to 5 mg, 10 mg or 15 mg of tirzepatide or placebo for 72 weeks, and its abstract on PubMed reports mean weight changes of 15.0, 19.5 and 20.9 percent against 3.1 percent.
A mean age of 45 with two thirds of participants female means a substantial number of women in the trial were in the age range in which menopause occurs. But neither the abstract nor the label reports results by sex, by age band within adulthood, or by menopausal status, so nothing can be said from those sources about how that group fared relative to the whole. The trial’s results are for its population as a whole.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label does say about age and sex
Where the Zepbound® label mentions age and sex, it is in two places, and neither concerns menopause. In its geriatric use section it reports that 9 percent of treated patients in the two weight reduction trials were 65 or older and that no overall differences in safety or effectiveness were observed between those patients and younger adults. In its obstructive sleep apnea studies section it states that a reduction in the apnea-hypopnea index was observed irrespective of age, sex, ethnicity, baseline body mass index or baseline severity. Both are statements about the trial populations, not about menopause and not about any individual.
The label’s warnings apply regardless of life stage. The boxed warning about thyroid C-cell tumours, the contraindications, and the warnings about pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration and severe gastrointestinal reactions are the same for every adult the label covers.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What a review says about sex and response
A 2026 narrative review by Lopez Delgado and colleagues in Frontiers in Medicine, found through PubMed, examines why response to obesity medications varies between people. According to its abstract, response heterogeneity reflects interactions among central satiety and reward circuitry, baseline metabolic and glycemic status, sex, baseline adiposity, treatment indication, previous exposure to a GLP-1 medication, adherence and tolerability. Sex is on the list; menopause is not named, and the review’s conclusion is that precision approaches today rest on phenotype-guided treatment and early response monitoring rather than on any single characteristic.
That is as far as the published evidence this site uses goes. This guide found no label statement and no large trial specific to menopause, and it does not fill the gap with inference.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What this means when you talk to a provider
Because the sources are silent, the useful conversation is about you rather than about menopause in general. Tell your provider where you are in menopause and what symptoms you attribute to it. Tell them about any hormone therapy and every other medication you take, because the Zepbound® label states that tirzepatide delays gastric emptying and can affect the absorption of oral medications, and because the label asks providers to weigh the full picture. Describe what you have noticed about your weight over time, since the review names baseline adiposity and metabolic status among the things that shape response. And ask what the provider would consider a reasonable point to reassess; the review’s finding that early on-treatment change within 12 to 16 weeks is the most actionable predictor of longer-term outcomes is a published reference for that conversation.
The guide on this site to not losing weight on tirzepatide covers the wider question of variation, and the guide to pregnancy and fertility covers the reproductive sections of the labels, which remain relevant until menopause is complete.
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer. Clinical services for applicable programs are provided by Wasef Health, PC, and a licensed provider determines whether treatment is appropriate for each individual patient. Personalized Compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound®. This guide is general information and not medical advice, it states no outcome for anyone, and your provider is the person to ask.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.